Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models

Effects of a Mediterranean-Style Diet on the Need for Antihyperglycemic Drug Therapy in Patients With Newly Diagnosed Type 2 Diabetes

(2013) Katherine Esposito   ANNALS OF INTERNAL MEDICINE

Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function indb/dbmice

(2013) T Nagata et al.   BRITISH JOURNAL OF PHARMACOLOGY

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats

(2012) Takumi Nagata et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus

(2012) Muhammad A. Abdul-Ghani et al.   Current Diabetes Reports

Comment on: Vila et al. B-Type Natriuretic Peptide Modulates Ghrelin, Hunger, and Satiety in Healthy Men. Diabetes 2012;61:2592-2596

(2012) J. Jordan et al.   DIABETES

Standards of Medical Care in Diabetes--2013

(2012)   DIABETES CARE

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

(2012) D. Devineni et al.   DIABETES OBESITY & METABOLISM

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

(2012) Jan Bolinder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

(2012) Yoshihito Ohtake et al.   JOURNAL OF MEDICINAL CHEMISTRY

Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats

(2012) James J. Devenny et al.   Obesity

Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models

(2012) Yin Liang et al.   PLoS One

Phantom and cadaver measurements of dose and dose distribution in micro-CT of the chest in mice

(2011) Thomas Rodt et al.   ACTA RADIOLOGICA

Non-alcoholic fatty liver disease

(2011) Briohny W. Smith et al.   CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES

Advances in the Treatment of Type 2 Diabetes Mellitus

(2010) Zafar H Israili   AMERICAN JOURNAL OF THERAPEUTICS

Macrophages, Inflammation, and Insulin Resistance

(2010) Jerrold M. Olefsky et al.   Annual Review of Physiology

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

(2009) B Komoroski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease

(2008) Robert R. Henry   CURRENT MEDICAL RESEARCH AND OPINION